Bharat Biotech. Hyderabad. Type of PAC (Supplement and Notifiable / Permission Granted by CDSCO) S. No Product
|
|
- Merryl Knight
- 6 years ago
- Views:
Transcription
1 Bharat Biotech Hyderabad S. No Product Type of PAC (Supplement and / Permission Granted by CDSCO) PAC Details Date of NOC in manufacturing process of Oral Polio F.No /BHARAT/(PACOPV)/13-BD in container closure of Poliomyelitis s (mopvs, bopv & topv), Live (Oral) Oral Polio s (mopv, bopv, topv) F.No /Bharat/PACPolio/13-BD Manufacture of Bivalent Poliomyelitis Type 1 & 3 Live (Oral)- 1.0 ml 10 doses presentation F.No /Bharat/PACbOPV/15-BD Revision of Package Insert of Biopolio B1 & 3 (Bivalent Poliomyelitis Type 1 & 3 Live (Oral)
2 F.No.12-26/Bharat-Bio/PAC-BiopolioB1/3/16-BD PAC for in the seal of Bivalent Poliomyelitis Vaccinr Type 1&3 Live (Oral) F.No12-97/BBIL/PACbOPV/16-BD Dated: Dy No For tightening the storage condition for Purified Inactivated Japanese Encephalitis Virus Bulk from 5 ± 3 C to -70 C ± 5 C Supplement F.No /BHARAT/(PACJE)/14-BD in the preservative for Purified Inactivated Japanese Encephalitis in PFS (JENVAC-PFS) Purified Inactivated Japanese Encephalitis Virus F.No /BBIL/PACJENVAC- PFS/15-BD Extension of shelf life for Purified inactivated Japanese Encephalitis Virus Bulk from 24 months to 36 months when stored at -70 C ± 5 C F.No /BBIL/PACJENVAC/16-BD
3 in the International nonproprietary name(inn) of JENVAC and JE Shield F. No /Bharat/PAC-JENVAC PFS/15BD Revision of package insert of Japanese Encephalitis Inactivated (adsorbed, human) F.No /BBIL/PAC-JE Vac/16-BD NOC for extension of shelf life of Rotavirus 116E Bulk (Live Attenuated) from 72 months to 120 months F.No /Bharat/PACRotavirus/14-BD PAC in the specifications for the drug product 3 Live Attenuated Oral Rotavirus 116 F.No /BBIL/PACRotavirus/16-BD d passage level of Rotavirus 116E- Working Virus Bank. F.No /BBIL/PACRotavirus/16-BD PAC for Revision of Packaging Material of Rotavirus (Live Attenuated, Oral)
4 F.No. : /BBIL/PACRotavirus/16-BD 4 Diphtheria, Tetanus & Pertussis (Comvac 3) Manufacture of Diphtheria, Tetanus and Pertussis in PFS Presentation /BBIL/PAC-DTP /15 BD s for elimination low vaccume drying step from the Bioprocess of Hib- PRP Bulk Haemophilus influenzae type b (Hib) conjugate F.No /BHARAT/(PACHib+J138 PRP-TT)/13-BD in drug substance manufacturing process of purified HIB -PRP-TT conjugate bulk (drug substance) F.No /Bharat Biotech/PAC- Hib PRP-14-BD
5 extension of shelf life of Haemophilus Influenzae Type b purified RP- TT conjugate Bulk (drug substance) from 12 months to 24 months F.No /BBIL/PAC-Hib PRP TT Bulk/15- BD Extension of shelf life from 2 years to 3 years for rabies vaccine (Vero Cell cultured) INDIRAB File No /BBIL/09BD/suppl Rabies, Human Tightening of the storage condition for purified BPL inactivated bulk of rabies antigen F.No /BHARAT/ (PACRabies)/ 13- J156BD Deletion of the acceleration degradation test from the release specification of rabies vaccine-ip F.No.12-13/BHARAT/ J158(PACRabies)/ 14- BD Extension of shelf life of Purified Rabies (Bulk) from 12 months to 24 months
6 F.No /Bharat/P AC-RabiesBulk/13-BD Addition of M/S. Global Pharma as additional source (supplier) of diluent 0.9% w/v NaCl which is used in manufacturing of Rabies & Haemophilus Influenzae Type b conjugate F.No.12-33/BHARAT/ PACNaCl/ 14-BD Recombinant Hepatitis B Manufacture of Recombinant Hepatitis B (Thiomersal free) in PFS presentation F.No.12-81/BBIL/PACRevacB/15BD change Shelf life extension of Vi Capsular Polysaccharide Typhoid 0.5ml in PFS & 5.0ml in vial from 24months to 36 months Vi Capsular Polysacchari de Typhoid Supplement change change F.No /Bharat/PACVi Capsular Typhoid /14-BD Elimination of low vacuum drying step from the Bioprocess (Bulk) F.No /BHARAT/(PAC-CDSTyphoid) Shelf life extension of Vi- Capsular Polysaccharide Typhoid Bulk from 24 months to 36 months F.No /Bharat/PACTyphoid/14-BD Usage of liquid Bulk for conjugation in manufacturing of Typhoid Vi- Capsular Polysaccharide- Tetanus Toxoid conjugate Bulk F.No.12-47/BBIL/PACTyphoid /15-BD
DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014.
DCVMN AND VACCINE SECURITY IN ASEAN REGION ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. Phuket - Thailand Developing Countries Vaccine Manufacturers Network (DCVMN)
More informationVaccines and other immunological antimicrobial therapy 1
Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that
More informationPractical Applications of Immunology. Chapter 18
Practical Applications of Immunology Chapter 18 I. Vaccines A. Definition A suspension of organisms or fractions of organisms that is used to induce immunity (immunologic memory). The mechanism of memory
More informationProspective Models of Vaccine Security Collaborations in Research and Development
Prospective Models of Vaccine Security Collaborations in Research and Development Georges Thiry, PhD IVI (International Vaccine Institute) Phuket, Oct 01, 2014 Content R&D Examples of collaborations from
More informationCPT 2016 Code Changes
CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer
More informationAnnex 1. WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine
WHO related to the manufacture and quality control of biological substances used in medicine WHO are intended to provide guidance to those responsible for the production of biological substances as well
More informationApproval / Acknowledgement Letter Ref No. / Diary no F.No.12-48/GSK/PAC- Synflorix/15-BD 25-Mar-15 2 GlaxoSmithKline Pharmaceuticals Limited.
1 GlaxoSmithKline Deletion of a n-significant in-process test limit during the purification process of the tetanus / diphtheria toxoids used in the manufacture of GSK's PCV vaccine [brand name: Synflorix]
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationPublic Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.
ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many Medical Policy Title: Immunization Coverage Document: ARB0454:04 Administered by: Public Statement: 1.
More informationCentral Inspection Plan Using Risk Based Approach Of Vaccine Manufacturing Units for 2017
, follow-up, failure A NORTH ZONE 1 M/s Biomed Pvt. Ltd, C-96, Site I, Bulandshahar Road, Ind. Area, Ghaziabad. 1. Oral Polio Vaccine IP, 2. Vi Typhoid Vaccine (Bio Typh TM ) IP, 3. Haemophilus Type-B
More informationCHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES
CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o
More informationPentabio Vaccine (DTP-HB-Hib)
SUMMARY OF PRODUCT CHARACTERISTICS Product Name Pharmaceutical Form Strength Presentation : Pentabio : Suspension for injection : 1, 5 and 10 doses : Box of 10 vials @ 0.5 ml Box of 10 vials @ 2.5 ml Box
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationTable Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines
Table Of Contents Executive Summary THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines THE MARKET Adult Preventative Vaccines THE MARKET TOTAL MARKET ISSUES AND
More information9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
More informationPREPARATION STANDARD MATERIAL HELD AT CODE WHO/BS DOCUMENT. 1st Reference Reagent, 2009
WHO International Biological Reference Preparations Held and Distributed by the WHO International Laboratories for Biological Standards Acellular pertussis vaccine for potency assay by modified mouse challenge
More informationCoverage of Vaccines Medicaid and Child Health Plus Members
Coverage of Vaccines Medicaid and Child Health Plus Members For children between the ages 0-18, routine recommended vaccinations are covered through Vaccines for Children program [VFC]. Fidelis Care will
More informationCopyright regulations Warning
COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright
More informationArmed Services Blood Program Immunization List
Immunization List NOTICE: The Department of Defense (DoD) assumes no risk for the use of this information by non-dod personnel, blood programs, or individual medical institutions. The use of this information
More informationVaccinology 101 for Fellows
Vaccinology 101 for Fellows Meg Fisher, MD Medical Director, The Children s Hospital Monmouth Medical Center An affiliate of the Saint Barnabas Health Care System Long Branch, NJ Disclosures I have no
More informationExpanded Programme on Immunization (EPI)
Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information Name of Manufacturer Prequalification Team WHO PUBLIC INSPECTION
More informationWHO International Biological Reference Preparations Held and distributed by the WHO International Laboratories for Biological Standards
WHO International Biological Preparations Anthrax spore vaccine. Lyophilized spore suspension of Bacillus anthracis strain 34 F2. 1 IU / ampoule. Anti-brucella abortus serum, bovine. Lyophilized. 1,000
More informationVaccination-Strategies
Vaccination-Strategies Active immunity produced by vaccine Immunity and immunologic memory similar to natural infection but without risk of disease. General Rule: The more similar a vaccine is to the disease-causing
More informationImmunizations for Children and Teens with Suppressed Immune Systems
Immunizations for Children and Teens with Suppressed Immune Systems Your child is starting treatment that will suppress the immune system. This will affect how your child s body responds to routine immunizations
More informationTemperature Intelligence Solutions. Thermostability of Vaccines
Thermostability of Vaccines Why are all vaccines sensitive to heat and some to freezing? Why is thermostability of vaccine important? What can be done to improve the thermostability of vaccines? Goals
More informationM I C R O B I O L O G Y
ninth edition TORTORA FUNKE CASE M I C R O B I O L O G Y a n i n t r o d u c t i o n 18 Practical Applications of Immunology PowerPoint Lecture Slide Presentation prepared by Christine L. Case Vaccine
More informationExpanded Programme on Immunization (EPI)
Sri Lanka 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationBirth 6 wk 10 wk 14 wk 18 wk 6 mo 9 mo 12 mo 15 mo 18 mo mo 2-3 Yr 4-6 Yr 7-10Yr Yr 13-18Yr
Vaccine BCG Age Birth 6 wk 10 wk 14 wk 18 wk 6 mo 9 mo 12 mo 15 mo 18 mo 19-23 mo 2-3 Yr 4-6 Yr 7-10Yr 11-12 Yr 13-18Yr BCG Hep B Hep B1 Hep B2 Hep B3 Polio OPV 0 IPV1 IPV2 IPV3 OPV1 OPV2 IPV B1 OPV3 DTP
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationProgramme update. Prequalification of Vaccines
Programme update Prequalification of Vaccines UN Prequalification of Medicines, Diagnostics and Vaccines 6th Consultative Stakeholder Meeting 4 April 2011 David Wood, WHO/IVB/QSS Outline Good news - A
More informationFamily and Travel Vaccinations
Family and Travel Vaccinations We offer the full range of baby, child and family vaccinations. We are able to tailor schedules to your child s needs or international schedule. We have a suggested vaccination
More informationExpanded Programme on Immunization (EPI)
Timor-Leste 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationChild Health and Disability Prevention (CHDP) Program Code Conversion
Child Health and Disability Prevention (CHDP) Program Code Conversion Health s All s are effective for dates of service on or after July 1, 2017. (Select s for laboratory-only providers with effective
More informationVACCINE MANAGEMENT. Recommendations for Handling and Storage of Selected Biologicals. January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES
VACCINE MANAGEMENT Recommendations for Handling and Storage of Selected Biologicals January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES DTaP: Diphtheria Toxoid, Tetanus Toxoid, Acellular Pertussis Vaccine
More informationThe administration of covered immunizations and vaccines also is covered.
Covered Benefit: Vaccines & Immunization Definitions: CMP Published: Yes No CMP Link: CPG Link: Pediatric, Adolescent and Adult Routine Preventative Services Immunizations and vaccinations for treatment
More informationThe administration of covered immunizations and vaccines also is covered.
Covered Benefit: Immunization & Vaccines Definitions: CMP Published: Yes No CMP Link: CPG Link: Pediatric, Adolescent and Adult Routine Preventative Services Immunizations and vaccinations for treatment
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Routine Immunizations Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 3 References... 7 Effective Date... 4/15/2018
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationStainless-steel vs Single-use: The Vaccines Perspective
Stainless-steel vs Single-use: The Vaccines Perspective CMO-Biomanufacturer Panel Tue 21 April, Noon-1:30pm, Exhibit Hall Daniel C.Vellom, PhD Sr. Director Global Technology Innovation 2015 INTERPHEX 1
More informationSyrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation
Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,
More informationExpanded Programme on Immunization (EPI)
Indonesia 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationBenefit Interpretation
Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents
More informationSchools. Kindergarten
1 of 5 7/29/2014 4:14 PM Schools North Carolina law requires all children in the state to receive certain immunizations. Records are checked when children enter school or child care. Kindergarten Vaccination
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More information14: Immunological products and vaccines
File name: Immunological Products and s Formulary BNF Original Date of issue: 30/10/2005 Last Reviewed: 23/11/2012 Version:4 Page 1 of 6 14: Immunological products and vaccines 14.1 Active immunity Live
More informationOut-of-Network providers require prior authorization to render services to Neighborhood members.
IMMUNIZATIONS AND VACCINES BILLING AND REIMBURSEMENT POLICY This payment policy applies to all in-network providers who render services to Neighborhood Health Plan of Rhode Island (Neighborhood) subscribers
More informationHistory of Vaccines. Stanley A. Plotkin ADVAC HISTORY /21/ :21 AM
History of Vaccines Stanley A. Plotkin ADVAC HISTORY 2014 5/21/2014 11:21 AM 1 Sources of Information on The History of Vaccines: Short: Medium: Long: Chapter 1 of the book Vaccines, By Plotkin and Plotkin
More informationBIOFARMA EXPERIENCE WITH ASEAN CTD. Novotel, Shanghai Day 4, Thursday 22 nd March 2018, CTD session
BIOFARMA EXPERIENCE WITH ASEAN CTD Novotel, Shanghai Day 4, Thursday 22 nd March 2018, CTD session ASEAN ASEAN CTD (ACTD) Established in Jakarta (ASEAN Secretariat), December 2016 Guideline of the agreed
More informationLichenase: a versatile, stable carrier molecule for vaccine and reagent development
Lichenase: a versatile, stable carrier molecule for vaccine and reagent development R. Mark Jones Center for Molecular Biotechnology, Fraunhofer USA New Cells, New Vaccines VII, From Protein to Product
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis-B (rdna) and Haemophilus type b Conjugate Vaccine (Adsorbed) I.P. Injectable, Suspension for injection. 2. QUALITATIVE
More informationVACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
More informationGuideline for the immunization of HIV infected persons in Sri Lanka
DOI: http://doi.org/10.4038/joshhm.v3i0.64 Guideline for the immunization of HIV infected persons in Sri Lanka Dr. M. K. Darshanie Mallikarachchi, Consultant Venereologist, Provincial General Hospital
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationRe: Revisions to Chapter III of the Communicable Disease Control Manual Immunization Program
1 August 17, 2004 ATTN: Medical Health Officers and Branch Offices Public Health Nursing Administrators and Assistant Administrators Holders of Communicable Disease Control Manuals Re: Revisions to Chapter
More informationCOMPOSITION OF VACCINE per 1 ml: not less than 30 OU/ml (not less than 8.0 IU/ml)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 QUINVAXEM in cpad DTwP HepB Hib fully liquid combination vaccine DESCRIPTION The vaccine is a homogeneous
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More information1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References...
1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References... 7 2 General Recommendations on Immunization Timing and Spacing of Vaccines...
More informationPlease read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture. Chapters 9, 17 and 8 for next Friday s lectures
Valerie Daggett Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture Chapters 9, 17 and 8 for next Friday s lectures ppt files for first 2 lectures Past exams Principles of
More informationAchievements in Public Health, Impact of Vaccines Universal... Children -- United States,
1 of 6 2/10/2005 7:40 PM Weekly April 02, 1999 / 48(12);243-248 Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children -- United States, 1990-1998 At the beginning
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationSanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines
Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases
More informationBy:Reham Alahmadi NOV The production of antibodies and vaccination technology
By:Reham Alahmadi NOV 2018 The production of antibodies and vaccination technology Antibody Production The blood contains two types of white blood cell or leukocyte Phagocytes ingest bacteria by endocytosis
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Section 7: Biological Product Information Standard #: 07.211 Created
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) I.P. Injectable, Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.5 ml contains:
More informationFrom: New York State Department of Health, Bureau of Communicable Disease Control, Immunization Program
November 3, 2008 To: Hospitals, Providers, Local Health Departments From: New York State Department of Health, Bureau of Communicable Disease Control, Immunization Program HEALTH ADVISORY: USE OF PENTACEL
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX Haemophilus type b conjugated vaccine IP 1. NAME OF THE MEDICINAL PRODUCT Haemophilus type b conjugated vaccine
More informationAdolescent vaccination strategies
Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za
More informationAppendix 1 Pregnancy Identification Algorithm
Appendix 1 Pregnancy Identification Algorithm We used the following procedure to identify unique pregnancies in Oregon Medicaid, Emergency Medicaid and Emergency Medicaid Plus claims data from January
More informationSUMMARY OF PRODUCT CHARACTRISTICS
1. NAME OF THE MEDICINAL PRODUCT Purified, Inactivated, Lyophilized Rabies Vaccine, Prepared on Vero Cells INDIRAB 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Qualitative Formula per dose of 0.5 ml (Single
More informationImmunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR
Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types
More informationImmunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Immunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1 Realize the significance
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET HIBERIX Haemophilus influenzae type b (Hib) powder and diluent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose
More informationModern Drug House.
+91-8048941768 Modern Drug House https://www.moderndrughouse.in/ We are one of the leading suppliers and traders of a wide range of Vaccine and Pharmaceutical Products. Owing to its effectiveness, purity
More informationAdvisory Committee on Immunization Practices VACCINE ACRONYMS
Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table of standardized
More informationPlease note the following changes to the Immunization Program:
1 August 22, 2003 ATTN: Medical Health Officers and Branch Offices Public Health Nursing Administrators and Assistant Administrators Holders of Communicable Disease Control Manuals Re: Revisions to the
More informationTable 1: Basic information ,000, (per 1,000 LB) 34.6 (per 1,000 LB) 174 (per 100,000 LB) District 712.
EPI history EPI launched in 978 with DPT, OPV, BCG and typhoid vaccines TT immunization of pregnant women introduced in 983 MCV introduced in 985 HepB piloted in 00 and made universal in 0 MCV introduced
More informationProcedure/Product Code Description
Proc. Type Code Procedure/Product Code Description ACA Primary Care Services Fees VFC 90585 TB $23.14 VFC 90632 Hep A $23.14 VFC 90633 Hep A $23.14 VFC 90634 Hep A $23.14 VFC 90636 Hep A - Hep B $23.14
More informationUNICEF Safe Injection Equipment Key highlights
Safe Injection Equipment VPPEF 03 October 2017 UNICEF Safe Injection Equipment Key highlights Nagwa Hasanin, HTC Vaccine Pharmaceutical form Route of administration Liquid Freeze- dried oral Inject Site
More informationSUMMARY OF PRODUCT CHARACTRISTICS
1. NAME OF THE MEDICINAL PRODUCT Typhoid (Vi Capsular Polysaccharide)-Tetanus Toxoid Conjugate Vaccine. Typbar-TCV 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Qualitative Formula per dose of 0.5 ml (Single
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationVaccine. Specific defenses Immunity. natural. acquired. Live vaccines. Killed Inactivated vaccines. Cellular fraction vaccines
Introduction Vaccine has been a importance medical breakthrough in preventing morbidity and mortality from infectious diseases worldwide. Vaccination has managed to eradicate the deadly and mutilating
More informationInterrupted primary series***
(Updated March 2017) Table 3: Recommendations* for Interrupted or Delayed Routine Immunization - Summary of WHO Position Papers Antigen Age of 1st Dose Doses in Primary Series (min interval between s)**
More informationSoonerCare Fax Blast
SoonerCare Fax Blast February 15, 2008 Subject: EPSDT and 4 th DPT/DTaP Encounters Dear Provider: Please note the following: EPSDT All encounters for EPSDT for 2007 dates of service must be filed before
More informationTarget Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationVaccine Label Examples
Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can
More informationUse of Infanrix -IPV+Hib in the infant primary immunisation schedule
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks
More informationPrimary Vaccine Container Selection in Developing Countries Safety. Neal Halsey Johns Hopkins Bloomberg School of Public Heath
Primary Vaccine Container Selection in Developing Countries Safety Neal Halsey Johns Hopkins Bloomberg School of Public Heath Issues Requested to Cover 1. Rates of contamination, needlesticks, etc. due
More informationEUROPEAN MEDICINES AGENCY DECISION. of 31 March 2009
European Medicines Agency Doc. Ref. EMEA/160106/2009 P/64/2009 EUROPEAN MEDICINES AGENCY DECISION of 31 March 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for Purified
More informationInterrupted primary series***
(Updated April 2018) Table 3: Recommendations* for Interrupted or Delayed Routine Immunization - Summary of WHO Position Papers Antigen Age of 1st Dose Doses in Primary Series (min interval between s)**
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationCHILDHOOD VACCINATION
EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,
More informationExperience with the first wp based fully liquid hexavalent vaccine.
Experience with the first wp based fully liquid hexavalent vaccine. EasySix TM Vaccine R K Suri Senior Advisor & Former Chief Executive- Biologicals Panacea Biotec Ltd New Delhi, INDIA October 31, 2018
More informationAll Kindergarteners and 4-6 year old transfer students. 4 doses DTP or DTaP 1 dose must be at or after 4 years of age. None
Parents Vaccines Required for School Entry in Michigan Whenever children are brought into group settings, there is a chance for diseases to spread. Children must follow state vaccine laws in order to attend
More informationAKE WITH Y KEEP AND T
VACCINATION RECORD Vaccination, the best protection This booklet is an important document. It is the only record of all the vaccines you have received. You will need it all your life, so keep it in a safe
More informationHow and Why Vaccines are Made. Stanley A. Plotkin
How and Why Vaccines are Made Stanley A. Plotkin Levine 2017 January 23, 2017 Vaccinology A combination of: Microbiology Immunology Epidemiology Public Health and Pharmacy 2 The impact of vaccination on
More information